News | Analytics Software | October 31, 2016

Children's Hospital of Philadelphia Recognized for Creating Venous Thromboembolism Recognition Technology

Hospital’s Information Services team created system that uses natural language processing to scan radiologist reports to identify patients potentially at high risk for hospital-acquired VTE

October 31, 2016 — In an effort to improve patient care, Children's Hospital of Philadelphia's (CHOP) Information Services team is using data and advanced analytics to screen patients for venous thromboembolism (VTE). This innovative technology is being honored by Drexel University and CIO.com in their inaugural Analytics 50 award ceremony, which will be held on Nov. 9, 2016 at Drexel University's LeBow College of Business.

VTE is currently the second-most common contributor to harm in hospitalized pediatric patients. If left untreated, it can result in a pulmonary embolism, infection or death. Using natural language processing (NLP), CHOP now scans radiologists' reports for designated keywords and phrases to provide a high level of accuracy in identifying and tracking patients who could be at risk for hospital-acquired VTE.

"Before creating this technology, VTE identification was dependent upon manually-generated clinical lists and post-discharge case reviews, both of which are time-consuming, error-prone and do not provide immediate identification," said John Martin, senior director of enterprise analytics at CHOP. "By using NLP, we automated the process and can identify at-risk patients more quickly, with high sensitivity and specificity."

CHOP was previously recognized nationally as a finalist for a Business Innovator Award in the 2016 InformationWeek Elite 100 ranking.

For more information: www.chop.edu

Related Content

FDA Clears First Neonatal Magnetic Resonance Imaging Device
Technology | Pediatric Imaging | July 21, 2017
The U.S. Food and Drug Administration (FDA) has cleared the first magnetic resonance imaging (MRI) device specifically...
SIIM Recognizes Innovators in Medical Imaging Informatics at 2017 Annual Meeting

Accepting the award on behalf of Arterys is Julia Geer shown with SIIM Chair Dr. Paul Nagy (left), and Innovation Challenge Co-Chair Dr. Ram Chadalavada (right)

News | Analytics Software | July 19, 2017
During the Society for Imaging Informatics in Medicine (SIIM) 2017 general closing session held in Pittsburgh, Fabien...
Vital's Practice Management Tool Showcased at AHRA 2017
Technology | Analytics Software | July 13, 2017
July 13, 2017 — Vital Images Inc.
Diagnostic Radiation Exposure Safe for Children, Experts State
News | Pediatric Imaging | June 21, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure to...
New Image Wisely Radiation Safety Case Discusses Child-Sizing CT Dose
News | Radiation Dose Management | June 19, 2017
The tenth special edition Image Wisely Radiation Safety Case is now available to help radiologists, imaging...
pediatric imaging
News | Pediatric Imaging | June 14, 2017
Despite evidence showing that the routine use of sonography in hospital emergency departments can safely improve care...
Vital Images to Address Specialized Workflow and Efficiency Challenges at SIIM 2017
News | Enterprise Imaging | June 01, 2017
An industry expert from Vital Images, Inc. (Vital) is participating in a discussion with the healthcare community on...
ACR Select Extended to Cover Pediatric Imaging Indications and Exams
News | Clinical Decision Support | May 17, 2017
May 17, 2017 — Through the support of the American College of Radiology and the contribution of leading experts from
Carestream Spotlights New Imaging Analytics Tools for Preventative Care at SIIM 2017, Clinical Collaboration Platform
News | Computer-Aided Detection Software | May 15, 2017
Carestream Health is demonstrating new imaging analytics tools that are being added to its Clinical Collaboration...
PET/CT Helps Predict Therapy Effectiveness in Pediatric Brain Tumors

FIGURE: MRI AND PET-MRI FUSION IMAGES OF PATIENTS WITH DIPG. Top row: Zr-89-bevacizumab PET (144 hrs p.i.) fused with T1-Gd weighted MRI per patient; middle row: T1-Gd weighted MRI; lower row: T2-weighted/FLAIR MR-images. Five tumors show variable uptake of Zr-89-bevacizumab (white arrows), with both PET negative and positive areas within each tumor. Two primary tumors are completely PET negative (Fig. 1C and 1E), while the T2 weighted images show tumor infiltration in the whole pons of both patients. In the middle row, the red arrows represent the areas of contrast enhancement within the tumor. In four out of five primary tumors, the PET-positive area corresponds with the contrast-enhancing area on MRI of the tumors (Fig. 1A, 1B, 1F and 1G). In Fig. 1C, the tumor shows an MRI contrast-enhancing area, while there is no Zr-89-bevacizumab uptake. Fig. 1D shows a PET positive tumor, while no Gd-enhancement is observed on MRI. Credit: Sophie Veldhuijzen van Zanten and Marc Jansen, VU University Medical Center, Amsterdam, The Netherlands.

News | PET-CT | May 02, 2017
In a first-ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron...
Overlay Init